This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Dog Hair Extract Study

This study has been completed.
ALK-Abelló A/S
Information provided by (Responsible Party):
Jennifer Brandorff, National Jewish Health Identifier:
First received: April 26, 2011
Last updated: March 27, 2017
Last verified: March 2017

Liquid allergen extracts contain proteins, such as (but not limited to) tree, weed, cat, cockroach, and nuts, and are used to identify allergies by observing the body's reaction to the introduction of extract underneath the skin. There are a few dog allergen extracts commercially available in the US for allergy testing; however, none of these products are standardized, meaning they are not required to be the same strength. Because some extracts are not as potent (strong) as others, it's possible that some patients' allergies are misdiagnosed. Typically, the most potent (strong), but safe extract should be used so that allergic patients are correctly diagnosed.

The purpose of this study is to compare the safety and potency of an investigational (not approved for use by the United States Food and Drug Administration [FDA]) dog allergen extract with two commercially available dog extracts, which are of differing potencies.

Condition Intervention
Potency of Dog Hair Extract Biological: Dog Hair Extract, ALK-Abelló, Inc.

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Participant
Primary Purpose: Other
Official Title: Dog Hair Evaluation Potency by Prick Skin Testing

Further study details as provided by Jennifer Brandorff, National Jewish Health:

Primary Outcome Measures:
  • End-point dilution giving a positive prick skin test in dog allergic subjects. [ Time Frame: Study Completion ]
    The concentration of each allergen extract which produced a 5 mm wheal for each subject will be calculated. From this, the relative potency of each extract will be calculated.

Enrollment: 15
Study Start Date: November 2010
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Dog Hair Extract, ALK-Abelló, Inc. Biological: Dog Hair Extract, ALK-Abelló, Inc.
ALK-Abelló dog epithelial 1:10w/v glycerin

Detailed Description:
This study is designed to assess the potency of a modified dog hair and dander extract in comparison with the two commercially available dog hair and dander extracts. This is a pilot study to estimate a target strength of dog extract in order to proceed to further studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must sign informed consent before completing any study procedure.
  • Age 18 years and ≤60 years.
  • Dog-sensitized patients as indicated by a mean wheal > 5 mm with the AP dog extract.
  • Females of child-bearing potential must have a negative pregnancy test the day of skin testing.
  • Patients who are able to understand the information given and be compliant with the protocol.

Exclusion Criteria:

  • Asthma requiring treatment with medications other than beta-2 inhaled agonists and montelukast inhibitors.
  • Patients with a history of asthma or wheezing with an FEV1 <80%.
  • Subjects who have taken an ocular or nasal antihistamine within 5 days prior to the procedures.
  • Patients who have received any desensitization for dog allergen in the past 5 years.
  • Patients with any past or current clinically significant condition that may affect the patient's participation or the outcome of the study to the discretion of the investigator. These include, but are not limited to, anaphylaxis with cardio-respiratory symptoms, chronic urticaria and angioedema unless related to dog exposure, severe atopic dermatitis, malignancy, cardiovascular, hepatic, renal, hematological, neurological, immunological, and endocrine disease.
  • Subjects taking beta blockers, ace inhibitors, continuous systemic corticotherapy, immunosuppressive drugs or monoamine oxidase inhibitors.
  • Use of H1 antagonists, tricyclic antidepressants and phenothiazines within 5 days prior to the testing.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01343420

United States, Colorado
National Jewish Health
Denver, Colorado, United States, 80206
Sponsors and Collaborators
National Jewish Health
ALK-Abelló A/S
Principal Investigator: Harold Nelson, M.D. National Jewish Health
  More Information

Responsible Party: Jennifer Brandorff, Regulatory Manager, National Jewish Health Identifier: NCT01343420     History of Changes
Other Study ID Numbers: ALK-Abelló Dog Allergen
Study First Received: April 26, 2011
Last Updated: March 27, 2017

Keywords provided by Jennifer Brandorff, National Jewish Health:
Skin tests
Dog Hair
Allergy Extract processed this record on June 22, 2017